Moleculin Biotech, Inc.

Moleculin Biotech (MBRX) shows no cyber incidents or major red-flag filings in our 90-day monitoring window, which suggests operational stability in the near term. However, low signal in a limited timeframe doesn't indicate comprehensive risk—biotech firms face persistent dilution pressures and financing volatility that extend beyond recent headlines. The full $49 Report adds a 12-month filing timeline, dilution risk scoring, complete 8-K context, financing history, and AI-driven risk signals that reveal structural vulnerabilities in early-stage biotech capital structures. That depth is what separates a snapshot from actionable due diligence.